Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Prothelia
Milford, Massachusetts, United Statesprothelia.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
As of 2025, Prothelia's lead candidate recombinant human Laminin-111 (rhLAM-111) is in preclinical development. The company has made progress in manufacturing the protein and is conducting pre-clinical studies to establish safe and effective dosing. Natural history studies are being conducted in collaboration with various organizations to establish clinical outcomes for future trials[2][4].
- Therapeutic areas
- Rare Diseases
- Modalities
- Recombinant protein
- Industry
- Biotech
02
Partnerships
Alexion PharmaceuticalsUniversity of Nevada
Beyond the preview
Go deeper on Prothelia.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Prothelia.